SEAT:NASDAQVivid Seats Inc. Analysis
Data as of 2026-04-30 - not real-time
$6.24
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Vivid Seats (SEAT) is trading at $6.24, well below its 20‑day SMA of $6.89 and 50‑day SMA of $6.45, indicating short‑term weakness. The RSI sits at 45.5, suggesting a neutral momentum, while the MACD line sits below its signal, flagging a bearish technical bias. Volatility is extreme at roughly 101% over the past 30 days and a computed beta of 2.08 points to a stock that swings far more than the market. Fundamentally, the company is in distress: revenue has fallen 36.5%, margins are deeply negative (operating margin –14.2%, profit margin –75.2%), and cash flow is heavily negative with $78.6 M in free‑cash‑flow deficit. The balance sheet shows $406 M of debt against modest cash of $102 M and a negative book value per share of –$7.91. Recent headlines report a sharp share‑price plunge following a bleak quarterly report, reinforcing the downside pressure.
Despite a low price‑to‑sales multiple of 0.12 and an implied upside of ~53% from current levels to the median analyst target of $9, the combination of deteriorating fundamentals, high volatility, and bearish technical signals suggest that any upside is speculative and comes with substantial risk.
Despite a low price‑to‑sales multiple of 0.12 and an implied upside of ~53% from current levels to the median analyst target of $9, the combination of deteriorating fundamentals, high volatility, and bearish technical signals suggest that any upside is speculative and comes with substantial risk.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Bearish MACD histogram and proximity to support level
- Extreme 30‑day volatility and high beta
- Negative earnings surprise and share‑price plunge in news
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Low price‑to‑sales ratio suggesting cheapness
- Continued negative cash flow and margins
- Potential for modest recovery if revenue stabilises
Long Term
> 3 yearsCautious
Model confidence: 8/10
Key Factors
- Sustained structural deficits (negative EPS, negative book value)
- High debt load relative to cash and earnings
- Persistent high volatility and weak industry fundamentals
Key Metrics & Analysis
Financial Health
Revenue Growth-36.50%
Profit Margin-75.21%
P/E Ratio-1.8
ROE-272.82%
ROA-3.11%
P/B Ratio-0.8
Op. Cash Flow$-91599000
Free Cash Flow$-78614128
Industry P/E18.7
Technical Analysis
TrendNeutral
RSI45.6
Support$5.90
Resistance$8.29
MA 20$6.89
MA 50$6.45
MA 200$11.69
MACDBearish
VolumeStable
Fear & Greed Index88.25
Valuation
Target Price$9.58
Upside/Downside53.55%
GradeUndervalued
TypeValue
Risk Assessment
Beta2.08
Volatility100.92%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.